Skip to main content
Close
Home
Society of Hospital Medicine
Presented by Society of Hospital Medicine
Home
Twitter Facebook LinkedIn Instagram YouTube Hospital Medicine Exchange Email RSS Feed

M. Alexander Otto

M. Alexander Otto began his reporting career early in 1999 covering the pharmaceutical industry for a national pharmacists' magazine and freelancing for the Washington Post and other newspapers. He then joined BNA, now part of Bloomberg News, covering health law and the protection of people and animals in medical research. Alex next worked for the McClatchy Company. Based on his work, Alex won a year-long Knight Science Journalism Fellowship to MIT in 2008-2009. He joined the company shortly thereafter. Alex has a newspaper journalism degree from Syracuse (N.Y.) University and a master's degree in medical science -- a physician assistant degree -- from George Washington University. Alex is based in Seattle.

News

FDA hints at deadlines to meet accelerated approval requirements

Author:
M. Alexander Otto
Publish date: February 16, 2022

In other countries, the public is protected from “stale claims of effectiveness.”

  • Read More

News

Shorter courses of chemo treatment taking hold in colon cancer

Author:
M. Alexander Otto
Publish date: February 11, 2022

The IDEA trial has led to a major change in stage III colon cancer treatment. Adjuvant colon cancer therapy is shifting toward the combination...

  • Read More

News

Black patients now central to lung cancer screening guidelines

Author:
M. Alexander Otto
Publish date: February 11, 2022

Guidelines were once written primarily with White patients in mind generalizing screening criteria across ethnically diverse populations which...

  • Read More

News

Yescarta label updated: Prophylactic steroids to prevent CRS

Author:
M. Alexander Otto
Publish date: February 2, 2022

New Yescarta labeling advises clinicians to consider using corticosteroids to ward off cytokine release syndrome.

  • Read More

News

Can immunotherapy replace surgery for stomach cancer?

Author:
M. Alexander Otto
Publish date: January 25, 2022

The complete pathologic response rate to neoadjuvant nivolumab/ipilimumab was 59%.

  • Read More

News

‘Highly encouraging’ MRD results for zanubrutinib add-on in CLL

Author:
M. Alexander Otto
Publish date: January 12, 2022

Blood and bone marrow MRD was undetectable in almost 90% of subjects after a median of 10 treatment cycles.

  • Read More

News

Fitusiran: Great ‘leap forward’ in hemophilia treatment

Author:
M. Alexander Otto
Publish date: December 17, 2021

Cost will be a major consideration if fitusiran is approved for the U.S. market.

  • Read More

News

DLBCL: PFS but no OS benefit with polatuzumab-vedotin add-on

Author:
M. Alexander Otto
Publish date: December 17, 2021

Pending additional follow-up for overall survival, is the extra cost worth it?

  • Read More

News

ASH studies look at racial disparities in ALL care, outcomes

Author:
M. Alexander Otto
Publish date: December 15, 2021

Findings of two studies on U.S. blood cancer care suggest that “structural racism” may play a role in worse outcomes among young Hispanic and...

  • Read More

News

Talk early to patients with high-risk AML about end-of-life decisions

Author:
M. Alexander Otto
Publish date: December 12, 2021

With nearly 40% of AML patients unable to take part in their own final code discussions, families struggle to guess what their loved ones would...

  • Read More

News

Myeloid patients respond robustly to Moderna COVID vaccine

Author:
M. Alexander Otto
Publish date: December 12, 2021

Among 46 patients, nearly all seroconverted after second shot.

  • Read More

News

FDA approves new interferon for polycythemia vera

Author:
M. Alexander Otto
Publish date: November 18, 2021

A longer half-life means dosing every 2 weeks, instead of weekly.

  • Read More

News

Tolerability doesn’t explain why kids do better than adults on ALL regimens

Author:
M. Alexander Otto
Publish date: November 8, 2021

Differences in tumor biology seem to be at play.

  • Read More

News

Genes related to osteosarcoma survival identified

Author:
M. Alexander Otto
Publish date: October 5, 2021

They predict survival and are also potential therapy targets.

  • Read More

News

Better survival with extended letrozole in early-stage breast cancer

Author:
M. Alexander Otto
Publish date: September 29, 2021

Guidelines for duration of endocrine therapy ‘should be updated.’

  • Read More

Pages

  • « first
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • last »
An Official Publication of the Society of Hospital Medicine

Society of Hospital Medicine
Twitter Facebook LinkedIn Instagram YouTube Hospital Medicine Exchange Email RSS Feed

Copyright  © 2023 Frontline Medical Communications Inc., Newark, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Menu Close